{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:25:16Z","timestamp":1786965916402,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06683-9","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:42:47Z","timestamp":1786963367000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bladder preservation vs. radical cystectomy for T2N0M0: trends and survival outcomes from SEER"],"prefix":"10.1007","volume":"44","author":[{"given":"Qiuming","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"6683_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"key":"6683_CR2","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3322\/caac.21631","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel VG, Oh WK, Galsky MD (2020) Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin 70:404\u2013423. https:\/\/doi.org\/10.3322\/caac.21631","journal-title":"CA Cancer J Clin"},{"key":"6683_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","volume":"69","author":"S Cambier","year":"2016","unstructured":"Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G et al (2016) Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1\u20133 Years of Maintenance Bacillus Calmette-Gu\u00e9rin. Eur Urol 69:60\u201369. https:\/\/doi.org\/10.1016\/j.eururo.2015.06.045","journal-title":"Eur Urol"},{"key":"6683_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1590\/s1677-5538.Ibju.2020.99.01","volume":"46","author":"J Hamad","year":"2020","unstructured":"Hamad J, McCloskey H, Milowsky MI, Royce T, Smith A (2020) Bladder preservation in muscle-invasive bladder cancer: a comprehensive review. Int Braz J Urol 46:169\u2013184. https:\/\/doi.org\/10.1590\/s1677-5538.Ibju.2020.99.01","journal-title":"Int Braz J Urol"},{"key":"6683_CR5","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1200\/jco.2014.57.5548","volume":"32","author":"RH Mak","year":"2014","unstructured":"Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP et al (2014) Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 32:3801\u20133809. https:\/\/doi.org\/10.1200\/jco.2014.57.5548","journal-title":"J Clin Oncol"},{"key":"6683_CR6","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3322\/caac.70019","volume":"75","author":"W Yip","year":"2025","unstructured":"Yip W, Jaime-Casas S, Kothari A, Sullivan M, Ballas LK, Escobar D et al (2025) Urothelial carcinoma: Perioperative considerations from top to bottom. CA Cancer J Clin 75:528\u2013551. https:\/\/doi.org\/10.3322\/caac.70019","journal-title":"CA Cancer J Clin"},{"key":"6683_CR7","doi-asserted-by":"publisher","first-page":"e6972","DOI":"10.1002\/cam4.6972","volume":"13","author":"NW Kang","year":"2024","unstructured":"Kang NW, Feng YH, Lin KL, Chen YC, Ho CH, Yang CC (2024) Comparative survival analysis of bladder preservation therapy versus radical cystectomy in muscle-invasive bladder cancer. Cancer Med 13:e6972. https:\/\/doi.org\/10.1002\/cam4.6972","journal-title":"Cancer Med"},{"key":"6683_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.euo.2018.07.006","volume":"2","author":"SB Williams","year":"2019","unstructured":"Williams SB, Hudgins HK, Ray-Zack MD, Chamie K, Smaldone MC, Boorjian SA et al (2019) Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. Eur Urol Oncol 2:119\u2013125. https:\/\/doi.org\/10.1016\/j.euo.2018.07.006","journal-title":"Eur Urol Oncol"},{"key":"6683_CR9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s00345-024-04892-8","volume":"42","author":"M Swinton","year":"2024","unstructured":"Swinton M, Devi A, Song YP, Hoskin P, Choudhury A (2024) Beyond surgery: bladder preservation and the role of systemic treatment in localised muscle-invasive bladder cancer. World J Urol 42:210. https:\/\/doi.org\/10.1007\/s00345-024-04892-8","journal-title":"World J Urol"},{"key":"6683_CR10","doi-asserted-by":"publisher","unstructured":"Palencia PS, Sivanesan N, Rahman S, Ghali F, Hesse D, Colberg J et al (2025) Partial Cystectomy for Muscle-Invasive Bladder Cancer. Cancers 17. https:\/\/doi.org\/10.3390\/cancers17152562","DOI":"10.3390\/cancers17152562"},{"key":"6683_CR11","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","volume":"87","author":"AG van der Heijden","year":"2025","unstructured":"van der Heijden AG, Bruins HM, Carrion A, Cathomas R, Comp\u00e9rat E, Dimitropoulos K et al (2025) European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines. Eur Urol 87:582\u2013600. https:\/\/doi.org\/10.1016\/j.eururo.2025.02.019","journal-title":"Eur Urol"},{"key":"6683_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11912-018-0711-0","volume":"20","author":"SB Johnson","year":"2018","unstructured":"Johnson SB, Yu JB (2018) Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer. Curr Oncol Rep 20:66. https:\/\/doi.org\/10.1007\/s11912-018-0711-0","journal-title":"Curr Oncol Rep"},{"key":"6683_CR13","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.ijrobp.2025.06.3866","volume":"123","author":"K Br\u00fcck","year":"2025","unstructured":"Br\u00fcck K, Atema V, Leliveld AM, Franckena M, Meijer RP, van der Heijden MS et al (2025) Health-Related Quality of Life in Patients Treated for Nonmetastatic Muscle-Invasive Bladder Cancer: Radical Cystectomy Versus Bladder-Preserving Therapy. Int J Radiat Oncol Biol Phys 123:1004\u20131017. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.06.3866","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6683_CR14","doi-asserted-by":"publisher","first-page":"e2517056","DOI":"10.1001\/jamanetworkopen.2025.17056","volume":"8","author":"DD Joyce","year":"2025","unstructured":"Joyce DD, Wymer KM, Graves JA, Boorjian SA, Gore JL, Khaki AR et al (2025) Cost-Effectiveness of Trimodal Therapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. JAMA Netw Open 8:e2517056. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.17056","journal-title":"JAMA Netw Open"},{"key":"6683_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.eururo.2012.11.015","volume":"63","author":"PJ Gray","year":"2013","unstructured":"Gray PJ, Fedewa SA, Shipley WU, Efstathiou JA, Lin CC, Zietman AL et al (2013) Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol 63:823\u2013829. https:\/\/doi.org\/10.1016\/j.eururo.2012.11.015","journal-title":"Eur Urol"},{"key":"6683_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.eururo.2017.03.019","volume":"73","author":"V Fonteyne","year":"2018","unstructured":"Fonteyne V, Ost P, Bellmunt J, Droz JP, Mongiat-Artus P, Inman B et al (2018) Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review. Eur Urol 73:40\u201350. https:\/\/doi.org\/10.1016\/j.eururo.2017.03.019","journal-title":"Eur Urol"},{"key":"6683_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2024.11.003","author":"A Matsukawa","year":"2024","unstructured":"Matsukawa A, Yanagisawa T, Miszczyk M, Kardoust Parizi M, Fazekas T, Tsuboi I et al (2024) Trimodality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Matched Cohort Studies. Eur Urol Focus. https:\/\/doi.org\/10.1016\/j.euf.2024.11.003","journal-title":"Eur Urol Focus"},{"key":"6683_CR18","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","volume":"198","author":"SS Chang","year":"2017","unstructured":"Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP et al (2017) Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA\/ASCO\/ASTRO\/SUO Guideline. J Urol 198:552\u2013559. https:\/\/doi.org\/10.1016\/j.juro.2017.04.086","journal-title":"J Urol"},{"key":"6683_CR19","doi-asserted-by":"publisher","first-page":"591","DOI":"10.6004\/jnccn.2019.5017","volume":"17","author":"TW Flaig","year":"2019","unstructured":"Flaig TW, Guidelines Updates NCCN (2019) Management of Muscle-Invasive Bladder Cancer. J Natl Compr Canc Netw 17:591\u2013593. https:\/\/doi.org\/10.6004\/jnccn.2019.5017","journal-title":"J Natl Compr Canc Netw"},{"key":"6683_CR20","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","volume":"71","author":"NJ Giacalone","year":"2017","unstructured":"Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM et al (2017) Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 71:952\u2013960. https:\/\/doi.org\/10.1016\/j.eururo.2016.12.020","journal-title":"Eur Urol"},{"key":"6683_CR21","doi-asserted-by":"publisher","unstructured":"Palencia PS, Sivanesan N, Rahman S, Ghali F, Hesse D, Colberg J et al (2025) Partial Cystectomy for Muscle-Invasive Bladder Cancer. Cancers (Basel) 17. https:\/\/doi.org\/10.3390\/cancers17152562","DOI":"10.3390\/cancers17152562"},{"key":"6683_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.semradonc.2022.10.004","volume":"33","author":"SC Kamran","year":"2023","unstructured":"Kamran SC, Efstathiou JA (2023) The Legacy of RTOG\/NRG Protocols in Shaping Current Bladder Preservation Therapy in North America. Semin Radiat Oncol 33:26\u201334. https:\/\/doi.org\/10.1016\/j.semradonc.2022.10.004","journal-title":"Semin Radiat Oncol"},{"key":"6683_CR23","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/s1470-2045(23)00170-5","volume":"24","author":"AR Zlotta","year":"2023","unstructured":"Zlotta AR, Ballas LK, Niemierko A, Lajkosz K, Kuk C, Miranda G et al (2023) Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol 24:669\u2013681. https:\/\/doi.org\/10.1016\/s1470-2045(23)00170-5","journal-title":"Lancet Oncol"},{"key":"6683_CR24","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1080\/14737140.2018.1535314","volume":"18","author":"J Mathes","year":"2018","unstructured":"Mathes J, Rausch S, Todenh\u00f6fer T, Stenzl A (2018) Trimodal therapy for muscle-invasive bladder cancer. Expert Rev Anticancer Ther 18:1219\u20131229. https:\/\/doi.org\/10.1080\/14737140.2018.1535314","journal-title":"Expert Rev Anticancer Ther"},{"key":"6683_CR25","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/jjco\/hyae164","volume":"55","author":"K Kobayashi","year":"2025","unstructured":"Kobayashi K, Fujii N, Shimizu K, Hitaka Y, Oka S, Nakamura K et al (2025) Comparative analysis of oncological outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer utilizing propensity score matching. Jpn J Clin Oncol 55:290\u2013296. https:\/\/doi.org\/10.1093\/jjco\/hyae164","journal-title":"Jpn J Clin Oncol"},{"key":"6683_CR26","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/s0022-5347(17)58915-6","volume":"116","author":"AC Novick","year":"1976","unstructured":"Novick AC, Stewart BH (1976) Partial cystectomy in the treatment of primary and secondary carcinoma of the bladder. J Urol 116:570\u2013574. https:\/\/doi.org\/10.1016\/s0022-5347(17)58915-6","journal-title":"J Urol"},{"key":"6683_CR27","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1016\/s0022-5347(06)00322-3","volume":"175","author":"W Kassouf","year":"2006","unstructured":"Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke A, Munsell MF et al (2006) Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol 175:2058\u20132062. https:\/\/doi.org\/10.1016\/s0022-5347(06)00322-3","journal-title":"J Urol"},{"key":"6683_CR28","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1442-2042.2012.02974.x","volume":"19","author":"F Koga","year":"2012","unstructured":"Koga F, Kihara K (2012) Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review. Int J Urol 19:388\u2013401. https:\/\/doi.org\/10.1111\/j.1442-2042.2012.02974.x","journal-title":"Int J Urol"},{"key":"6683_CR29","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.urology.2008.04.052","volume":"72","author":"MC Smaldone","year":"2008","unstructured":"Smaldone MC, Jacobs BL, Smaldone AM, Hrebinko RL Jr. (2008) Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma. Urology 72:613\u2013616. https:\/\/doi.org\/10.1016\/j.urology.2008.04.052","journal-title":"Urology"},{"key":"6683_CR30","doi-asserted-by":"publisher","first-page":"188e1","DOI":"10.1016\/j.urolonc.2024.11.021","volume":"43","author":"J Schmidt","year":"2025","unstructured":"Schmidt J, Furlano K, Kellmer P, Krause H, Klatte T, Miller K et al (2025) Retrospective analysis of partial cystectomy in patients with muscle-invasive urothelial carcinoma: A German single-center experience. Urol Oncol 43:188e1\u2013188e8. https:\/\/doi.org\/10.1016\/j.urolonc.2024.11.021","journal-title":"Urol Oncol"},{"key":"6683_CR31","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"C Pfister","year":"2021","unstructured":"Pfister C, Gravis G, Fl\u00e9chon A, Souli\u00e9 M, Guy L, Laguerre B et al (2021) Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG\/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. Eur Urol 79:214\u2013221. https:\/\/doi.org\/10.1016\/j.eururo.2020.08.024","journal-title":"Eur Urol"},{"key":"6683_CR32","doi-asserted-by":"publisher","unstructured":"Kohut-Jackson A, Orf J, Barresi D, Davaro F, Hamilton Z (2024) Age related trends in the utilization of neoadjuvant chemotherapy for muscle invasive bladder cancer. Urol Oncol 42. https:\/\/doi.org\/10.1016\/j.urolonc.2024.01.006. 160.e25-160.e31","DOI":"10.1016\/j.urolonc.2024.01.006"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06683-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06683-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06683-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:42:48Z","timestamp":1786963368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06683-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6683"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06683-9","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"31 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"575"}}